Welcome to our dedicated page for BETTER THERAPEUTICS news (Ticker: BTTX), a resource for investors and traders seeking the latest updates and insights on BETTER THERAPEUTICS stock.
Better Therapeutics Inc. (BTTX) is at the forefront of developing prescription digital therapeutics aimed at treating chronic diseases. The company, formerly known as Farewell, leverages a unique combination of software, human coaching enhanced by artificial intelligence, and advanced analytics to address the underlying behaviors causing most chronic conditions. This innovative approach offers scalable solutions capable of impacting millions of lives.
Better Therapeutics' digital therapeutics are grounded in solid evidence and align with existing clinical treatment guidelines. They can be integrated with other interventions or used independently, providing flexible and effective treatment options. The company's non-drug solutions are pivotal in reducing the health and financial burdens of chronic diseases on individuals, healthcare payers, and the broader healthcare system.
Recent achievements include significant advancements in their AI-driven coaching systems and the successful integration of their digital therapeutics into various healthcare settings. Better Therapeutics is continually expanding its partnerships and collaborations to further enhance the reach and effectiveness of its products.
The company's financial health reflects steady growth, driven by its innovative products and expanding market presence. Better Therapeutics remains committed to advancing its mission of improving chronic disease management through cutting-edge digital solutions.
News
Rhea-AI Summary
Better Therapeutics, Inc. (BTTX) announced the termination of employees and exploration of strategic alternatives, including potential wind-down. The Company faces delisting from Nasdaq unless compliance is regained. Safe Harbor Statement included.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-82.84%
Tags
-
Rhea-AI Summary
Better Therapeutics (BTTX) partners with ACLM to offer one million prescriptions of AspyreRx to underserved communities affected by type 2 diabetes, aiming to improve diabetes outcomes in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.26%
Tags
-
Rhea-AI Summary
Better Therapeutics, Inc. (BTTX) is set to present 180-day outcomes data at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in March 2024. The company will showcase the effectiveness of AspyreRx™ in treating type 2 diabetes, demonstrating significant improvements in various health parameters. Moreover, Better Therapeutics will host an educational session to discuss the benefits of AspyreRx and its combination with glucagon-like peptide 1 (GLP-1) agonists.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.78%
Tags
Rhea-AI Summary
RedChip Companies will air interviews with Better Therapeutics, Inc. (Nasdaq:BTTX) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Better Therapeutics offers a groundbreaking approach to managing cardiometabolic diseases with its FDA-authorized product AspyreRx™, showcasing significant outcomes in treating type 2 diabetes. Biotricity revolutionizes cardiac care with remote diagnostic solutions, capturing an 8% market share in cardiology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
-
Rhea-AI Summary
Better Therapeutics (BTTX) receives FDA Breakthrough Device Designation for its novel Cognitive Behavioral Therapy platform to potentially treat metabolic dysfunction-associated steatohepatitis, showcasing promising clinical study results and paving the way for strategic partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.38%
Tags
-
Rhea-AI Summary
Better Therapeutics Inc. (NASDAQ: BTTX) has entered into a rebate agreement with a leading Pharmacy Benefit Manager, effective January 1, 2024, providing plan participants the ability to add AspyreRx™ to their formularies with rebate eligibility. This agreement opens up an important pathway for access to treatment for millions of patients with type 2 diabetes, demonstrating recognition of the value proposition of innovative solutions like AspyreRx and representing an important step toward increasing accessibility and coverage of the product for patients in need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.16%
Tags
Rhea-AI Summary
Better Therapeutics Inc. (NASDAQ: BTTX) has announced the publication of health economic data for its prescription-only digital behavioral treatment for type 2 diabetes (T2D), AspyreRx. The study found that AspyreRx plus standard of care was estimated to be superior to SoC alone, providing more life years and improvements in quality of life at a lower cost. From a healthcare payer perspective, AspyreRx plus SoC was dominant, with gains in quality-adjusted life years (QALYs) and cost savings of $7,343 per patient over the lifetime horizon. The study supports the potential efficacy and economic viability of digital therapeutics, recognizing the cost-effectiveness of integrating digital therapeutics into mainstream clinical practice. The estimated national cost of diabetes in 2022 was $412.9 billion, making the publication of this data crucial in driving sustainable solutions that can benefit both patients and the overall healthcare system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
-
Rhea-AI Summary
Better Therapeutics Inc. (BTTX) and Glooko, Inc. have announced a partnership to integrate Better Therapeutics’ AspyreRx™ digital behavioral treatment for type 2 diabetes (T2D) into Glooko’s diabetes management platform. This collaboration aims to enable healthcare providers in the United States to identify suitable patients for AspyreRx, facilitate prescriptions, and track patients throughout their treatment. Glooko’s solutions have aided over 3.4 million people with diabetes in the U.S. and are utilized in nearly 5,000 clinic locations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
-
Rhea-AI Summary
Better Therapeutics, Inc. (NASDAQ: BTTX) has requested Breakthrough Device Designation from the FDA for its prescription digital therapeutics to treat MASLD and MASH, conditions affecting millions of Americans with no approved treatments. The request follows the successful LivVita Liver Study, showing promising results in reducing liver fat and improving liver health. The company's fiscal year 2023 ended with $4.2 million in cash and cash equivalents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.31%
Tags
Rhea-AI Summary
Better Therapeutics, Inc. (BTTX) extends cash runway to demonstrate commercial traction with AspyreRx in Type 2 Diabetes. The company negotiated an amendment to its debt facility, implemented cost-saving measures, and expects to improve its financial position by approximately $5 million through the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.54%
Tags
FAQ
What is the current stock price of BETTER THERAPEUTICS (BTTX)?
The current stock price of BETTER THERAPEUTICS (BTTX) is $0.0001 as of September 13, 2024.
What is the market cap of BETTER THERAPEUTICS (BTTX)?
The market cap of BETTER THERAPEUTICS (BTTX) is approximately 5.5K.
What does Better Therapeutics Inc. do?
Better Therapeutics Inc. develops prescription digital therapeutics for treating chronic diseases using a blend of software, AI-enhanced human coaching, and advanced analytics.
How do Better Therapeutics' solutions work?
Their solutions target the behaviors causing chronic conditions, using evidence-based digital therapeutics that fit within clinical guidelines and can be scaled to impact millions.
What makes Better Therapeutics' approach unique?
The company combines digital therapeutics with AI-enhanced human coaching and advanced analytics, offering scalable non-drug treatment options for chronic diseases.
Can Better Therapeutics' products be used with other treatments?
Yes, their digital therapeutics can be used independently or integrated with other clinical interventions.
What recent achievements has Better Therapeutics made?
They have advanced their AI-driven coaching systems and successfully integrated their therapeutics into various healthcare settings, expanding their impact.
How does Better Therapeutics impact healthcare costs?
Their non-drug treatments aim to reduce the health and cost burdens of chronic diseases on individuals and healthcare systems.
What evidence supports Better Therapeutics' products?
Their digital therapeutics are based on well-established evidence and align with current clinical treatment guidelines, ensuring efficacy and reliability.
Who can benefit from Better Therapeutics' solutions?
Individuals with chronic diseases, healthcare providers, and payers can benefit from their innovative, scalable digital therapeutics.
What is the financial condition of Better Therapeutics?
The company shows steady growth driven by its innovative products and expanding market presence, reflecting a healthy financial outlook.
What is the mission of Better Therapeutics?
Their mission is to improve chronic disease management and reduce healthcare costs through advanced digital therapeutics.
BETTER THERAPEUTICS INC